Jeffrey S. Wefel
University of Texas MD Anderson Cancer Center
Quality of lifeCancerInternal medicineSurgeryNeuropsychologyPathologyOncologyRandomized controlled trialCognitionNeurocognitiveIntensive care medicinePhysical therapyTemozolomideGliomaTrail Making TestVerbal learningIn patientRadiation therapyClinical trialMedicine
Publications 184
#1Caroline Chung (University of Texas MD Anderson Cancer Center)H-Index: 19
#1Kyle R. Noll (University of Texas MD Anderson Cancer Center)H-Index: 11
#2Amanda L King (NIH: National Institutes of Health)H-Index: 1
Last. Jeffrey S. Wefel (University of Texas MD Anderson Cancer Center)H-Index: 31
view all 6 authors...
Patients with brain tumors experience great symptom burden across various domains of functioning, with associated decreases in health-related quality of life and general well-being. Impaired neurocognitive functioning is among the primary concerns of these patients. Unfortunately, most patients will experience such impairment at some point in the disease. However, impaired neurocognitive functioning, symptom burden, and well-being vary according numerous patient-, tumor-, and treatment-related f...
#1Paul D. Brown (Mayo Clinic)H-Index: 95
#2Caroline Chung (University of Texas MD Anderson Cancer Center)H-Index: 19
Last. M.F. McAleer (University of Texas MD Anderson Cancer Center)H-Index: 6
view all 20 authors...
BACKGROUND To determine if proton radiotherapy (PT), compared to intensity modulated radiotherapy (IMRT), delayed time to cognitive failure in patients with newly diagnosed glioblastoma. METHODS Eligible patients were randomized unblinded to PT vs. IMRT. The primary endpoint was time to cognitive failure. Secondary endpoints included overall survival (OS), intracranial progression-free survival (PFS), toxicity, and patient-reported outcomes. RESULTS A total of 90 patients were enrolled and 67 we...
#2Martin KleinH-Index: 63
Last. Mitchel S. BergerH-Index: 133
view all 5 authors...
#1Jeffrey S. Wefel (University of Texas MD Anderson Cancer Center)H-Index: 31
#2Terri S. Armstrong (University of Texas Health Science Center at Houston)H-Index: 34
Last. Minesh P. Mehta (UMB: University of Maryland, Baltimore)H-Index: 112
view all 13 authors...
BACKGROUND Results of NRG Oncology RTOG 0825 reported adding bevacizumab to standard chemoradiation did not significantly improve survival endpoints and resulted in greater decline in neurocognitive function (NCF) and patient reported outcomes (PRO) over time in bevacizumab treated patients. The present report provides additional results of patient centered outcomes over time and their prognostic association with survival endpoints. METHODS NCF tests, MD Anderson Symptom Inventory brain tumor mo...
#1Jaime A. QuirarteH-Index: 1
#2Vinodh A. KumarH-Index: 10
Last. Frederick F. LangH-Index: 76
view all 6 authors...
Supplementary motor area (SMA) syndrome is well known; however, the mechanism underlying recovery from language SMA syndrome is unclear. Herein the authors report the case of a right-handed woman with speech aphasia following resection of an oligodendroglioma located in the anterior aspect of the left superior frontal gyrus. The patient exhibited language SMA syndrome, and functional MRI (fMRI) findings 12 days postoperatively demonstrated a complete shift of blood oxygen level-dependent (BOLD) ...
#1Kurt A. Jaeckle (Mayo Clinic)H-Index: 64
#2Karla V. Ballman (Cornell University)H-Index: 87
Last. Michael Weller (UZH: University of Zurich)H-Index: 156
view all 23 authors...
BACKGROUND We report the analysis involving patients treated on the initial CODEL design. METHODS Adults (>18) with newly-diagnosed 1p/19q WHO grade III oligodendroglioma were randomized to RT (5940 cGy) alone (Arm A); RT with concomitant and adjuvant temozolomide (TMZ) (Arm B); or TMZ alone (Arm C). Primary endpoint was overall survival (OS), Arm A versus B. Secondary comparisons were performed for OS and progression-free survival (PFS), comparing pooled RT arms versus TMZ-alone arm. RESULTS Th...
#1Philip C. De Witt Hamer (VU: VU University Amsterdam)H-Index: 26
#2Martin Klein (VU: VU University Amsterdam)H-Index: 63
Last. Mitchel S. Berger (UCSF: University of California, San Francisco)H-Index: 133
view all 5 authors...
Functional outcome following glioma surgery is defined as how the patient functions or feels. Functional outcome is a coprimary end point of surgery in patients with diffuse glioma, together with oncological outcome. In this review, we structure the functional outcome measurements following glioma surgery as reported in the last 5 yr. We review various perspectives on functional outcome of glioma surgery with available measures, and offer suggestions for their use. From the recent neurosurgical ...
#1Kyle R. Noll (University of Texas MD Anderson Cancer Center)H-Index: 11
#2Henry S Chen (University of Texas MD Anderson Cancer Center)H-Index: 1
Last. Ho Ling Liu (University of Texas MD Anderson Cancer Center)H-Index: 10
view all 12 authors...
BACKGROUND Decline in neurocognitive functioning (NCF) often occurs following brain tumor resection. Functional connectomics have shown how neurologic insults disrupt cerebral networks underlying NCF, though studies involving patients with brain tumors are lacking. OBJECTIVE To investigate the impact of brain tumor resection upon the connectome and relationships with NCF outcome in the early postoperative period. METHODS A total of 15 right-handed adults with left perisylvian glioma underwent re...
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.